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Journal of Clinical Psychopharmacology • Volume 39, Number 6, Novemcommunicated to the physician of the participant. In both the deviating geno-
type control arm (DG-C) and the nonrandomized control arm, the physician
of the participants was not informed about the genotype and the associated
dosing advise. The primary outcome was the time needed to reach adequate
drug levels: (1) blood levels within the therapeutic range and (2) no dose ad-
justments within the previous 3 weeks.
Findings/Results: No significant difference was observed in mean time
to reach adequate dose or time to adequate dose between DG-I and DG-C.
Compared with the nonrandomized control arm group, adequate drug levels
were reached significantly faster in the DG-I group (log-rank test;P = 0.004),
and there was a similar nonsignificant trend for the DG-C group (log-rank
test; P = 0.087).
Implications/Conclusions: The results of this study do not support
pharmacogenetic CYP2D6 screening to accelerate dose adjustment for
nortriptyline and venlafaxine in older patients with depression.
Key Words: pharmacogenetic screening, CYP2D6 genotyping,
nortriptyline, venlafaxine, elderly
(J Clin Psychopharmacol 2019;39: 583–590)
M ajor depressive disorder is a potential chronic disorder withan estimated prevalence rate around 4.7%,1 and rates are
highest in the older population (7.2% in more than 75 years).2
The burden of major depressive disorder does not only affect men-
tal health but also physical health and quality of life.3
Efficacies of different antidepressant drugs are comparable,
but drugs have different adverse drug profiles. Because selective se-
rotonin reuptake inhibitors (SSRIs) have a more favorable adverse
effect profile, they are often recommended as first-choice treatment.
If the SSRI is not effective or not tolerated, an alternative treatment
can be considered.4 Another SSRI, a tricyclic antidepressant, for ex-
ample, nortriptyline, in older persons; a serotonin-norepinephrine re-
uptake inhibitor, mostly venlafaxine; and a monoamine oxidase
inhibitor are all part of these alternative treatment options. Because
the duration of untreated depression is a predictor for poor prognosis
in the already fragile elderly population, rapid dose finding of the sec-
ondary treatment option with minimal adverse events is essential.5
Nortriptyline and venlafaxine are both metabolized by the
highly polymorphic cytochrome P450 2D6 (CYP2D6) isoenzyme:
nortiptyline to the active metabolite E-10-hydroxynortriptyline half
as potent as nortriptyline, venlafaxine to the equipotent metabolite
O-desmethylvenlafaxine. Most often, the genetic differences are
classified into 4 different phenotype groups: poor metabolizers
(PMs), intermediate metabolizers (IMs), extensive metabolizers
(EMs), and ultrarapid metabolizers (UMs).6 The UM phenotype
is associated with therapeutic inefficacy, whereas an increased risk
of toxicity and adverse effects has been reported in the PM and IMber/December 2019 www.psychopharmacology.com 583
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(TDM) helps to find optimal dosage for individual patients and to
check adherence. Besides TDM, it has been put forward that infor-
mation on the CYP2D6 genotype can further improve dose finding,
but scientific evidence from rigorous trials is lacking.8–10 We also
showed this in a post hoc analysis of an earlier smaller clinical trial
in elderly treated with nortriptyline and venlafaxine.11 In the
Netherlands, national guidelines are established based on system-
atic review of the literature, with therapeutic recommendations for
nortriptyline and venlafaxine based on genotype information for
CYP2D6.10 These guidelines have been acknowledged by inter-
national initiatives such as the PharmGKB database. The influ-
ence of genotype at elderly patients treated with nortriptyline
and venlafaxine in the Netherlands has been previously studied,
indicating results from genotyping of elderly gives a good indica-
tion of a patient's phenotype if coadministered medication, and
the “intermediate genotype” is taken into account.11 This current
trial aimed to investigate the clinical effects of implementation
of the Dutch guideline for dose adaptations of nortriptyline and
venlafaxine based on CYP2D6 genotype.
The primary objective of this pragmatic prospective random-
ized trial was to determine the effect of CYP2D6 screening among
elderly (CYSCE) on the time needed to obtain therapeutic drug
levels as an accepted proxy for adequate treatment in depres-
sion.12,13 The secondary objectives were to determine the effect
of pharmacogenetics screening for CYP2D6 on adverse drug re-
actions, self-reported functional health status, and quality of life.
MATERIALS AND METHODS
Study Design
The trial protocol was published earlier.14 In short, the trial
was designed as a multicenter randomized controlled trial across
multiple old age psychiatry and geriatric mental health care insti-
tutions across the Netherlands. Ethical approval was obtained by
an independent ethics committee (RTPO-Leeuwarden-NL; file
number: NL40925.099.12). Patients were recruited by their physi-
cian or a research nurse. The study was built up as a 2-part in-
formed consent design in which patients had to give separate
written informed consent for both parts. The first part of the study
consisted of a basic genotype screening in which each eligible pa-
tient (see eligibility criteria in the Participants section hereinafter)
starting with nortriptyline or venlafaxinewas asked permission for
genotyping. Patients with PM, IM, and UM genotypes and a se-
lection of the patients with an EM genotype were selected for par-
ticipation in the second (trial) part of the study and were asked for
a second informed consent. From the patients with the EM geno-
type, a random selection of patients was allocated to an additional
(external cohort) reference group. If selected for the trial part of
the study, eligible patients were invited for a baseline visit in
which baseline characteristics were determined (Table 1). At 2,
4, and 6 weeks after baseline, blood samples were collected to es-
timate the blood level of the drug by a “dried blood spot” (DBS)
method. This method was validated for TDM by means of a liquid
chromatography–mass spectrometrymethod.12,13 In addition, ques-
tionnaires concerning adverse drug reactions, quality of life, sever-
ity of depression, and medication dose were administered. Patients,
for whom a clinically acceptable dose was not established within
6weeks, were followed up for an additional 2weeks until dose find-
ing was completed. These additional 2-week samples were col-
lected only for those patients who had a dose change 3 weeks or
less before the moment the sample was collected, because it can
take up to 2 to 3 weeks for patients with a PM profile to reach
steady-state concentration for nortriptyline.15 This study is reported584 www.psychopharmacology.comaccording to the CONSORT guidelines16,17 for reporting random-
ized trials and was registered at ClinicalTrials.gov (Identifier:
NCT01778907) before the start of the trial.
Participants
Patients were eligible for participation in this study if they
were 60 years or older, diagnosed by the physician as having a ma-
jor depression according to theDiagnostic and Statistical Manual
of Mental Disorders (Fourth Edition–Text Revision) and criteria
(code: 296.2x or 296.3x). Furthermore, only those patients initiat-
ing with either nortriptyline or venlafaxine were considered eligi-
ble, and the patient needed to be able to understand the informed
consent procedures. Patients were excluded for trial participation
if there was known liver cell damage, a proxy for a poor hepatic
function (aspartate aminotransferase and alanine aminotransferase
or γ-glutamyl transferase ≥ twice the maximal reference value),
impaired renal function (estimated glomerular filtration rate
<30 mL/min) in combination with venlafaxine use, or if patients
were currently using interacting drugs that influence blood levels
of nortriptyline or venlafaxine (ie, patients using terbinafine, keto-
conazole, voriconazole, kinidine, propafenon, cimetidine, fluoxe-
tine, paroxetine, bupropion, duloxetine, sertraline, abirateron,
cinacalcet, rifampicine, or ritanovir). Drug interactionswere based
on pharmacy interaction monitoring software, summary of prod-
uct characteristics, and Flockhart's interaction table (Flockhart
D. Drug interactions: cytochrome P450 drug interaction table).
The pharmacokinetic interaction of CYP2D6 in monotherapy
with nortriptyline or venlafaxine was studied in this trial; there-
fore, the primary outcome was the time needed to reach adequate
drug levels. As such, possible pharmacodynamic interactions with
comedication were not taking into account.
CYP2D6 Genotyping
The first part of the study consisted of CYP2D6 genotyping
using a DBS sample.18 Single-nucleotide polymorphism were
assessed for the *3, *4, *5, *6, *10, *17, and *41 alleles together
with the duplications of the CYP2D6 gene. Based on the enzyme
activity of the different alleles, a prediction was made for the phe-
notype after the Royal Dutch Pharmacists Association CYP2D6
guidelines and the Clinical Pharmacogenetics Implementation
Consortium translation guidelines.12,13
Presence of 2 alleles lacking enzyme activity (*3, *4, *5, *6)
is considered as a PM phenotype. One allele lacking enzyme activ-
ity paired with an allele with decreased enzyme activity (*10, *17,
*41) results in an IM phenotype. In addition, the presence of only
one allele lacking enzyme activity or 2 alleles with decreased en-
zyme activity also results in an IM phenotype. A duplication of
the CYP2D6 gene results in an UM phenotype prediction, unless
it is combinedwith any allelewith reduced or lacking enzyme activ-
ity, an IM duplication. With this genotype, a prediction of the over-
all enzymatic activity and the subsequent dosing advice cannot be
given, and therefore, these genotypes are excluded.
Randomization and Allocation
Patients participating in the main study with a PM, IM, or
UM genotype were selected and randomly allocated by computer
(1:1) to either the “deviating genotype intervention” arm (DG-I)
or the “deviating genotype control” arm (DG-C). An additional
sample of patients with the EM genotype was allocated to a third
“normal genotype control” arm (NG-C) to be able to compare
prognosis with a natural course patient group and to control for
potential information bias. Because it was expected that patients
with the EM genotype are more prevalent than patients with a de-
viating genotype,6 and to prevent any potential time-dependent© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
TABLE 1. Overview of the Baseline Characteristics of the Different Intervention Groups in Trial
Randomized Trial Nonrandomized Trial
P
Informed (DG-I; n = 27) Not informed (DG-C; n = 22 External Control (NG-C; n = 57)
n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD)
Sex (female) 14 (51.9) 14 (63.6) 38 (66.7) 0.420*
Age, y 70.2 (7.3) 68.5 (5.1) 71.8 (7.2) 0.137†
Setting
Ambulant 14 (51.9) 13 (59.1) 28 (49.1) 0.729*
Clinical 13 (48.1) 9 (40.9) 29 (50.9)
Depression
296.2x 11 (40.7) 10 (45.5) 20 (35.1) 0.676*
296.3x 16 (59.3) 12 (54.5) 37 (64.9)
MADRS score 29.4 (8.6) 28.9 (7.8) 29.5 (9.2) 0.958†
Medication
Nortriptyline 18 (66.7) 13 (59.1) 36 (63.2) 0.861*
Venlafaxine 9 (33.3) 9 (40.9) 21 (36.8)
Starting dose, mg
Nortriptyline 18.1 (10.9) 18.1 (7.8) 22.6 (14.7) 0.547†
Venlafaxine 62.5 (18.8) 45.8 (16.5) 46.4 (16.4) 0.444†
Other medication (yes) 26 (96.3) 19 (86.4) 49 (86.0) 0.351*
Comorbidity (yes) 26 (96.3) 19 (86.4) 42 (73.7) 0.035*
Comorbidities (frequency) 2.6 (1.6) 1.9 (1.5) 2.4 (2.5) 0.151†
Genotype
EM *1/*1 37 (64.9%)
*1/*41 8 (14.0%)
*1/*10 3 (5.3%)
IM *1/*3 1 (3.7%) *1/*4 6 (27.2%) *1/*4 5 (8.8%)
*1/*4 9 (33.3%) *1/*5 1 (4.5%) *1/*6 2 (3.5%)
*1/*5 3 (11.1%) *1/*6 2 (9.1%) *1/*5 1 (1.8%)
*4/*10 1 (3.7%) *4/*10 1 (4.5%) *1/*3 1 (1.8%)
*4/*41 1 (3.7%) *4/*41 3 (13.6%)
*10/*41 1 (3.7%)
UM *1/*41 DUP 1 (3.7%) *1/*1 DUP 1 (4.5%)
*1/*1 DUP 1 (3.7%)
PM *3/*3 2 (7.4%) *3/*4 1 (4.5%)
*4/*4 5 (18.5%) *4/*4 7 (31.8%)
*3/*4 1 (2.7%)
*4/*5 1 (3.7%)
*Pearson χ2 test of all 3 groups.
†One-way analysis of variance.
MADRS indicates Montgomery-Åsberg Depression Rating Scale.15
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NG-C armwas dependent on the number of patients in the other trial
arms. During the trial, patients were not informed about their geno-
type or trial status. After completion of the trial, the genotypic infor-
mation of the control groups was communicated to the physician.
DG-I Arm
TheDG-I arm included patients with a PM, IM, or UMgeno-
type. The specific genotype accompanied by dosing advice was
directly communicated to the physician approximately 14 days af-
ter inclusion, which coincides with the first visit after the start of
treatment. The advice contained a standardized dosing recom-
mendation of the Royal Dutch Pharmacists Association based
on the patients' genotype and the prescribed drug (nortriptyline/© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.venlafaxine).12,13 For nortriptyline, the advice was given to adjust
to 50% (PM), 75% (IM), 100% (EM), and 150% (UM) of the
standard dose. Within the venlafaxine users, the advice of adjust-
ment to 75% (PM), 100% (EM), and 150% (UM) of the standard
dose was given to the physician. Based on the literature, no advice
could be given to the IM venlafaxine users, and therefore, TDM
was advised to their physician. The genotype-based recommenda-
tion was given on top of care and monitoring of drug use as usual,
for example, TDM.
DG-C Arm and NG-C Arm
The DG-C arm included patients with a deviating genotype,
PM, IM, or UM genotype, and the NG-C arm included patients
with a normal (EM) genotype. In contrast to patients in thewww.psychopharmacology.com 585
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genotype and the associated dosing advise of patients in both con-
trol arms. In addition, the physician was blinded for the difference
between both control arms to ensure representation of all the geno-
types in the control group and prevent dose adjustment based on
the participation in this study. During the trial, the genotyping
method had to be transferred to a different laboratory and location,
due to an unforeseen end of service of the primary laboratory. Al-
though a continuity of the same genotyping method was estab-
lished, this caused a temporarily delay in the genotyping of the
*5 allele and duplications. Because this delay in *5 genotyping
and duplications, only the prediction of the IM phenotype and
the subsequent dosing advise was hindered. To maintain continu-
ity at the recruiting sites, a second external control group (n = 10)
was added to the study halfway through the trial: the IM control
arm (IM-C). The addition of this extra control arm kept the ran-
domization of the trial arms (DG-I and DG-C) intact, and there-
fore, the delay in advice did not affect the study randomization
or the outcome. Results of genotype testing and dosing advice
of the IM-C arm were not communicated to the physician. Both
external control groups were combined and labeled as NG-C for
the treating physician.Outcomes
Primary Outcome
The primary outcome was the time in days needed to reach
an adequate drug level of nortriptyline or venlafaxine. Adequate drug
levels were defined as (1) blood levels within the therapeutic range as
determined by a DBS and (2) no dose adjustments within the pre-
vious 3 weeks. Therapeutic ranges according to the current Dutch
Clinical Pharmacy guidelines (NVZA) were followed, suggesting
nortriptyline levels between 50 and 150 μg/L and venlafaxine +
O-desmethylvenlafaxine levels between 250 and 750 μg/L (during
the trial, the reference value of the guideline was adjusted to
100–400 μg/L after an update of literature19 and used as further
reference value of the therapeutic range in this study).
Secondary Outcomes
Secondary outcomes were the frequency, severity (ie, mild,
moderate, and serious), and total sum of adverse effects measured
by a shorter and modified version of the Antidepressant Side-
Effect Checklist,20 and quality of life measured by the EuroQol
5D-3L (EQ5D-3L; Dutch score range, −0.329 to 1.000) and the
EuroQol visual analog scale (EQ-Vas; score range, 1–100).21 Sever-
ity of depression was measured by the Quick Inventory of Depres-
sive Symptomatology Self-Reported Questionnaire (QIDS-SR;
score range, 0–27), to determine possible differences in treatment
between groups related to the severity of depression instead of the
genotype-based intervention.22 All secondary outcomes, except
for the adverse effects, were measured by a telephone interview
from visit 2 till end point, every 2 weeks. Adverse effects were
assessed by the physician before start of the treatment and during
the trial every 2 weeks. In this way, we were able to correct for
symptoms of depression, age-related physical symptoms, or other
underlying physical diseases, which are often perceived by the pa-
tient as adverse effects of the antidepressant.20 Because genotype
information was available at visit 2, we expected the largest impact
on secondary outcomes to be at visit 3. Therefore, we also assessed
the difference between trial groups in frequency and severity of ad-
verse effects between baseline and visit 3. In addition, we deter-
mined the differences in self-reported functional health status and
general and disease-specific quality of life (EQ5D-3L; EQ-VAS)
and severity of depression (QIDS-SR) between visit 2 and visit 3.586 www.psychopharmacology.comStatistical Analysis and Report
Baseline characteristics were presented using descriptive sta-
tistics including means for continuous variables and percentages
for categorical variables. Analytical statistics to estimate differ-
ences between the groups of patients who were lost to follow-up
versus patients who completed the trial as well as between the dif-
ferent study arms were determined by t tests for continuous vari-
ables and χ2 tests for categorical variables.
The primary analysis assessed the mean time (in days)
needed to obtain adequate drug levels. Because a part of the study
population did not reach adequate drug levels, we also performed
a Kaplan-Meier analysis with a log-rank test to analyze the sur-
vival rate of adequate drug levels between the different trial groups
(survival = nonadequate drug level). A cutoff value of 70 days was
used for each participant as being the end of the observation pe-
riod to prevent crossing of the different survival curves (Fig. 2).
Sensitivity analyses were performed to account for the robustness
of our results, in which the cutoff value was changed to 80 and
100 days, the primary outcome was stratified into the different
medication groups (nortriptyline and venlafaxine), and a separa-
tion was made between the clinical and ambulant patients. To de-
termine the effect of dose of nortriptyline or venlafaxine on the
time to reach adequate drug levels, we compared the different dos-
ing levels at the end point for each patient, that is, the visit during
which adequate dosing was reached, or when no adequate dosing
was reached the last visit was taken as end point, by Kruskal-
Wallis test. In addition, we performed a Kaplan-Meier analysis
to analyze the effect of the different genotype groups (EM, IM,
PM, and UM) on time to reach adequate drug levels. Analysis
of variance or Kruskal-Wallis test was applied to test for potential
differences of secondary outcome measures between the trial
groups and the external reference group. A P value of 0.05 was
considered statistically significant. The statistical analyses were




In total, 199 of 202 patients gave informed consent for the
first phase of the trial and offered CYP2D6 genotyping. Eighteen
patients did not proceed in the study because they did not meet the
inclusion criteria or had one or more exclusion items. Overall,
23 (12.6%) of the patients were labeled to be PM, 68 (37.2%)
IM, 87 (47.5%) EM, 3 (1.6%) UM, and 2 (1.1%) IM with dupli-
cations. The 2 IMs with duplications were also excluded from
the study based on their genotype.
Inclusion of the study took place between February 2013 and
February 2017. The last follow-up visit was held in May 2017.
Figure 1 shows the flowchart of the entire CYSCE trial and in-
cluded patients followed up to 7 visits.
In total, 181 adults were considered for inclusion in the study.
Table 1 gives an overview of the baseline characteristics of the dif-
ferent intervention groups of patients who finished the trial
(N = 106). No significant differences were observed between the
different trial groups except for difference in the presence of comor-
bidities (DG-I, n = 26/27 [96.3%]; DG-C, n = 19/22 [84.4%]; NG-I,
n = 52/57 [73.7%]; P = 0.035). In a similar secondary analysis, we
compared the patients who finished the trial (n = 106) with patients
who did not participate in the complete trial (n = 75) because of be-
ing lost to follow-up, not being selected for the trial, or not signing
the second informed consent form. We only found a significant
difference (P = 0.006) in mean age between the finished trial
group (mean [SD] age, 70.7 [6.9] years’ n = 106) and the not© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
FIGURE 1. Flowchart of the CYSCE trial. IC, informed consent; IM-C/EM-C, IM/EM control arm = NG-C; IMdup, IMs with duplications;
LTFU, lost to follow-up.
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years, n = 32).Primary Outcome
The results of the primary outcome per trial group are presented
in Figure 2. Actual plasma concentration values are presented in Sup-
plementary Table S1, Supplemental Digital Content 1, http://links.
lww.com/JCP/A624. In total, 24 (88.9%) of the DG-I group reached
an adequate drug level of nortriptyline or venlafaxine in 39.3 (12.3)
days on average, compared with 16 (72.7%) of the DG-C group
(mean [SD] days, 39.6 [10.5]) and 39 (68.4%) of the NG-C group
(mean [SD] days, 48.1 [11.5]). No difference (P = 0.663) was ob-
served between the DG-I group and the DG-C group in mean time
to reach adequate dosing; however, a difference (P = 0.003) was ob-
served between the 2 deviating genotype groups and the NG-C
group (mean [SD] days: DG-I, 42.7 [15.2], n = 27; DG-C, 44.5© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.[13.0], n = 22; NG-C, 52.8 [13.0], n = 57). The Kaplan-Meier sur-
vival curve estimated that there was a significant difference (log-
rank test; P = 0.013) between the 3 trial groups (DG-I, n = 27;
DG-C, n = 22; NG-I, n = 57; Fig. 2). When comparing the survival
curves of the DG-C group and the DG-I group, no significant dif-
ference was observed (log-rank test; P = 0.425). Compared with
the NG-C group, the DG-I group was significantly faster in
reaching adequate drug levels, as assessed by the Kaplan-Meier sur-
vival curve estimate (log-rank test; P = 0.004), whereas the DG-C
did not show a significant difference compared with the NG-C
group (log-rank test; P = 0.087). These results did not change
when increasing the cutoff value of 70 to 80 or 100 days, stratify-
ing the outcome per medication group or separating the clinical
and ambulant patients.
A significant difference was observed in the dosing of nor-
triptyline between the 3 groups (median [interquartile range] dos-
ing per day at end point: DG-I [n = 18], 50.0 [50.0–75.0] mg;www.psychopharmacology.com 587
FIGURE 2. Survival curve of time to reach adequate drug levels of nortriptyline or venlafaxine per trial group.
TABLE 2. The Mean Difference in Self-Reported Quality of Life
(EQ5D-3L; Dutch Score Range, −0.329 to 1.000; EQ-VAS, Score
Range, 0–100) and Severity Score of Depression (QIDS-SR;
Score Range, 0–27) Per Trial Group Between Visit 2 and Visit 3
Trial Group n Mean Difference (SD) P*
EQ5D-3L score DG-I 19 0.09 (0.14) 0.747
DG-C 20 0.04 (0.25)
NG-C 39 0.08 (0.25)
EQ-VAS score DG-I 18 9.72 (13.88) 0.231
DG-C 20 1.25 (9.30)
NG-C 39 4.36 (18.00)
QIDS-SR score DG-I 18 −1.28 (4.00) 0.220
DG-C 20 −1.75 (4.34)
NG-C 38 −3.03 (3.41)
*One-way analysis of variance.
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[50.0–100.0] mg; Kruskal-Wallis test, P = 0.035) and between
the DG-I group and the NG-C group (Kruskal-Wallis test,
P = 0.035). The results were not affected after the exclusion of
the UM group. No significant difference was observed in the dos-
ing of venlafaxine between the 3 groups. The Kaplan-Meier sur-
vival curve estimated that there was a significant difference (log-
rank test;P < 0.001) in time to reach adequate drug levels between
the 4 genotype groups (EM [n = 48], IM [n = 38], PM [n = 17],
UM [n = 3]; Supplementary Figure S1, Supplemental Digital
Content 2, http://links.lww.com/JCP/A625). The UM and PM
groups reached the adequate drug dose faster compared with the
EM group (log-rank test, P < 0.001). When comparing the sur-
vival curves without the UM group, still an overall significant dif-
ference was observed (log-rank test, P = 0.006).
Secondary Outcomes
The differences between trial groups in overall frequency and
overall severity scores of adverse effects in both nortriptyline and
venlafaxine were all not statistically significant. Stratification into
the different medication groups (nortriptyline and venlafaxine)
did not yield a different result. Looking at the differences between
visit 1 and visit 3 in frequency and severity of adverse effects strat-
ified between trial groups, significant differences were observed
in the frequency of adverse effects (mean [SD] difference: DG-I,
1.48 [4.92]; DG-C, 2.09 [4.85]; NG-C, −2.51 [5.22]; P < 0.001)
and the frequency of serious adverse effects (mean [SD] differ-
ence: DG-I, 0.37 [1.08]; DG-C, 0.59 [1.37]; NG-C, −0.37
[1.29]; P < 0.001; Supplementary Figure S2, Supplemental Digi-
tal Content 2, http://links.lww.com/JCP/A625). In Table 2, the
mean difference between visit 2 and visit 3 of the trial of self-
reported quality of life per trial group is reported. No significant
differences were observed. Table 2 also shows themean difference
between visit 2 and visit 3 of the trial of average severity score of
depression per trial group. No significant difference was observed
between the different trial groups.
DISCUSSION
Our study results revealed that there is no difference in the time
needed to reach adequate drug levelswhen providingCYP2D6 geno-
type information, compared with no information, to the physician of588 www.psychopharmacology.compatients with deviating genotype. No difference in dose at end point
was observed between the 2 groups, which could indicate a lack of
genotype-based dose prescription by the physicians. The DG-I arm
differed significantly from the external control group (NG-C) in time
needed to reach adequate drug levels, most likely caused by a lower
dose needed to reach adequate dosing for deviating genotypes, dom-
inated by the IM and PM genotypes. Alternatively, the difference be-
tween the DG-I arm and the external control group could have been
caused by the CYP2D6 phenotype variability. The interindividual
variability is low or absent for both IMs and PMs (DG-I, DG-C),
whereas the variability in EMs (NG-C) is generally extensive due
to additional sources of variability, for example, presence of rare
2D6 variants or nongenetic factors affecting CYP2D6 phenotype.23
Because we wanted to investigate the clinical effects of implementa-
tion of the Dutch guideline, we did not analyze different phenotypes
as a separate subgroup. The difference in frequency of adverse effects
and frequency of serious adverse effects between baseline and visit
3 was significantly lower in the external control group comparedwith
the deviating genotype groups (DG-I and DG-C). This would also
match the interpretation that deviating genotypes (dominated by IM
and PM genotypes) start with a dose closer to the effective dose than
EM-genotypes, which leads to a higher drug blood level. When© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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measure, no general effect of CYP2D6 genotyping information was
seen on each of these secondary outcome measures. It could be
questioned whether changes in quality of life and depressive symp-
tom severity are detectable in such short period of time.
The analyses at baseline revealed that the different treatment
groups were comparable for most of the measured baseline character-
istics. The presence of somatic comorbidities was significantly more
frequent in the deviating genotype groups than in the control group.
A possible explanation could be that a deviating genotype is related
to frailty, although this was not seen in other clinical treatment param-
eters, like severity of depression or medication use. The higher pres-
ence of comorbidities could also have confounded the difference
between time to reach adequate drug levels between the external con-
trol group and the 2 deviating genotype arms. However, because of
multiple testing of different variables between the different trial groups,
the difference in the presence of comorbidities could also be based on
chance. In addition, because therewas by design no difference in base-
line characteristics between the deviating genotype trial arms, this
could not explain the absence of an effect of genotyping on time to
reach adequate drug levels between these 2 randomized trial groups.
Based on the nortriptyline and venlafaxine genotype-based
dose adjustment guidelines and the related research,12,24,25 we ex-
pected that the implementation of pharmacogenetics in clinical
practice would affect the adequate treatment for patients in a pos-
itive way. Although the effect of genotype on metabolic capacity
of specific psychotropic drugs like nortriptyline and venlafaxine
is well known, clinical effectiveness is dependent on more factors.
Dose adjustments based on genotype may not be informative
enough to make a clinical impact on, for example, drug efficacy
and prevention of adverse drug events.26 This is in line with previ-
ous research on the effect of genotyping on treatment efficacy in
depressed patients.27–29 However, the observation that the EM ge-
notypes needed a longer time to reach an adequate drug level is an
interesting finding, considering that most of the current pharma-
cogenetic guidelines aim at dose reduction among patients with
a decreased metabolic activity. Therefore, the beneficial effects
of genotyping in depressed patients might be in a faster titration
among patients with an EM genotype, but research into the effect
of supplying genotype information in the first weeks of the treat-
ment for EM patients is required.
The mean age of the patients that finished our trial was on aver-
age 4 years lower compared with the nonselected normal genotype
arm and those lost to follow-up. This could have affected the represen-
tativeness of the external control group (NG-C) for time to reach ade-
quate drug levels, but cannot explain the absence of effect between the
2 deviating genotype arms and the absence of effect in adverse effects
because therewas no difference inmean age at baseline. Itmight, how-
ever, be speculated that present clinical practice in this elderly popula-
tion seems to be based more on the patient characteristics of PM and
IM genotypes, and that knowledge of the EM genotype would allow
for a faster increase in dosing than usual and therefore lead to a more
adequate treatment for EM genotype patients. This is corroborated by
the significantly lower frequencyof total and serious adverse effects on
baseline compared with visit 3 in the EM genotype group. However,
this should be investigated in a future clinical trial.
The percentage of patients with the PM genotype is relatively
high, 12.6% (8% observed by Tamminga et al30), but because of the
limited number of patients, interpretation can only be speculative.Strengths
To our knowledge, this is the first and only pragmatic ran-
domized clinical trial examining the effect of pharmacogenetic
screening for CYP2D6 among elderly patients starting therapy© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.with nortriptyline or venlafaxine. The pragmatic design of this
study allows for greater external validity comparedwith usual ran-
domized controlled trial designs and therefore better applicability
to clinical practice.
Limitations
However, the results of this study should be considered in the
context of a few possible limitations. First, patients who finished
the trial were significantly younger compared with patients who
did not finish the trial. Although genetic differences are not depen-
dent on age, the relative effect of genotype information could be
more substantial in the fragile older population, which would be
underestimated in our younger elderly population. However, there
is no scientific evidence that a difference of 4 years in age could
clinically impact the effect of pharmacogenetic screening among
elderly. Second, as mentioned previously, it is possible that physi-
cians are already experienced in the dose finding of patients with
IM and PM genotype in particular by means of TDM, possibly
strengthened by clinical and scientific knowledge regarding ad-
verse events in an already fragile population and the presence of
genotypic diversity among these patients.31 This may have caused
the lacking effect of providing genotype information because clin-
ical practice is already dosing the patients with IM and PM geno-
type correctly. However, the effect of genotype information on the
EM genotype patients is missing in our trial, because this group
was considered as a control group. Because the genotype advice
was given to the treating physician after start of treatment, the ef-
fect of the genotype information could be limited. Genotype infor-
mation is becoming more readily available, which could also
improve the impact of genotyping. Another possibility of the lack-
ing effect of genotype information could be the restriction of a
faster dose adjustment in an ambulant setting due to logistical
problems. However, based on our results, no difference was ob-
served between clinical and ambulant patients. Lastly, we did
not meet the required number of patients included according to
the sample size calculation before the conduct of the study. Based
on our primary power calculation, a minimum of 48 participants
followed up until adequate drug dose was needed per treatment
arm.14 The primary hypothesis of the effect of genotyping was a
reduction of 50% in time to reach adequate drug levels of nortrip-
tyline or venlafaxine in weeks. Taking into account the current
distribution of time in days to reach adequate dosing in days in
the DG-C group and a reduction of 50% in the DG-I group, this
resulted in an estimated post hoc power of 100%. This indicates
that we could not reject the null hypothesis that there is no differ-
ence between the group of 50% or more with 100% certainty.
In conclusion, the addition of CYP2D6 genotype to optimize
drug dosing in older persons with depression and who start with nor-
triptyline or venlafaxine does not affect the adequate treatment for
this patient population. Because our trial was set in older patients, it
is uncertain how results may be applicable to younger patients.
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